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Objective: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed 
after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS 
group). If we expect that complete resection cannot be achieved by IDS, debulking surgery 
is performed after administering additional 3 cycles of chemotherapy without postoperative 
chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and 
determined their serum cancer antigen 125 (CA125) levels to predict complete surgery.
Methods: A retrospective chart review of all stage III and IV ovarian, fallopian tube, and 
peritoneal cancer patients treated with NAC in 2007–2016 was conducted.
Results: About 117 patients comprised the IDS group and 26 comprised the Add-C group. 
Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on 
progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the 
IDS group. Multivariate analysis revealed that patients who developed residual disease after 
surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45–3.28) 
and OS (HR=2.33; 95% CI=1.43–3.79), and those who received <6 cycles of chemotherapy 
had worse PFS (HR=5.30; 95% CI=2.56–10.99) and OS (HR=3.05; 95% CI=1.46–6.38). The 
preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method.
Conclusions: Administering 3 additional cycles of chemotherapy followed by debulking 
surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative 
chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of 
achieving complete surgery.
Keywords: Ovarian Neoplasm; Neoadjuvant Therapy; Cytoreduction Surgical Procedures; 
CA-125 Antigen
INTRODUCTION
The standard treatment for advanced ovarian cancer is primary debulking surgery (PDS) 
to completely resect all macroscopically visible diseases followed by taxane and platinum-
based adjuvant chemotherapy; however, incomplete surgery of any macroscopic residual 
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disease is associated with poor progression-free survival (PFS) and overall survival (OS) [1,2]. 
Neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) have been proposed 
as alternative treatment strategies for patients with advanced ovarian cancer who were unable 
to undergo complete debulking surgery [3-5]. Several published clinical trials demonstrated 
that the patients received 3 or 4 cycles of NAC and adjuvant chemotherapy [3-6]. Complete 
surgery, that is, the complete removal of macroscopic residual disease, is associated with 
better survival outcome when performed using either PDS or NAC-IDS approach [1-6].
The number of gynecologic oncologists who prefer the NAC-IDS approach is increasing. 
However, there is no consensus regarding the optimal number of chemotherapy cycles to 
be administered before and after IDS. Several retrospective studies revealed the impact of 
the number of NAC cycles on prognosis [7-12]. Preoperative evaluation of complete surgery 
is necessary because it is directly linked to patients' survival outcome. Several studies have 
investigated the preoperative serum cancer antigen 125 (CA125) level as a predictor of 
achieving complete surgery by IDS [13-17].
In our institution, IDS was performed after 3 cycles of NAC followed by 3 cycles of 
postoperative chemotherapy in patients with unresectable advanced ovarian cancer by PDS. 
However, in patients who were not expected to achieve complete surgery by IDS, debulking 
surgery was performed after administering additional 3 cycles of chemotherapy without any 
postoperative chemotherapy (Add-C). The present study aimed to evaluate the efficacy of 
administering an additional 3 cycles of chemotherapy followed by debulking surgery after 3 
cycles of NAC on the survival of patients with advanced ovarian cancer. Moreover, we aimed 
to investigate the serum CA125 levels to predict complete surgery in patients treated with NAC.
MATERIALS AND METHODS
1. The treatment strategy in our institution
The treatment strategy used in our institution is shown in Supplementary Fig. 1. Standard 
treatment for ovarian, fallopian tube, and peritoneal cancers was PDS with or without 
systemic chemotherapy. Surgery included total abdominal hysterectomy, bilateral salpingo-
oophorectomy, and omentectomy with or without retroperitoneal lymphadenectomy. 
Maximal effort was made to achieve complete surgery. All patients received combination 
chemotherapy with taxane and carboplatin. NAC was used in patients with stage IV disease, 
poor Eastern Cooperative Oncology Group performance status (2–4), or unresectable 
abdominal diseases, detected on image, such as bulky upper abdominal disease and 
multiple peritoneal metastases. We reevaluated the resectability on image after 3 cycle of 
NAC. IDS was performed followed by 3 cycles of postoperative chemotherapy in patients 
who were expected to achieve complete surgery by IDS. However, debulking surgery was 
performed after administering additional 3 cycles of chemotherapy without any postoperative 
chemotherapy in patients with unresectable diseases (bulky upper abdominal disease and 
multiple peritoneal metastases). Patients at our institutions usually received 6 cycles of NAC 
and did not usually undergo postoperative chemotherapy. No evidence exists to suggest that 
more than 6 cycles of chemotherapy result in a better outcome for front-line chemotherapy 
for International Federation of Gynecology and Obstetrics (FIGO) stage II–IV epithelial 
ovarian cancer [18]. We believe that the evidence also applies to the NAC approach.
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2. Data collection
This retrospective study was approved by the Institutional Review Board of the National 
Cancer Center Hospital (2018-120). We analyzed the medical records of patients with 
pathologically confirmed ovarian, fallopian tube, and peritoneal cancer who received 
treatment at the National Cancer Center Hospital between August 2007 and December 
2016. Patients who underwent PDS, had FIGO (2014) stage I or II, received <3 cycles of NAC, 
and had no surgical adaptation were excluded. Patients' prognoses and data on age, serum 
CA125 levels before treatment and surgery, FIGO stage, clinical TNM classification, tumor 
histological type, operation timing, resection status after debulking surgery, and cycles 
of NAC and number of chemotherapy cycles (NAC and postoperative chemotherapy) were 
obtained from medical records. The IDS group comprised patients who were planned to 
undergo IDS after receiving 3 cycles of chemotherapy, while the Add-C group comprised 
patients who were planned to undergo additional chemotherapy after initially receiving 
3 cycles of chemotherapy. Following the Japan Clinical Oncology Group (JCOG) 0602 
trial, some patients were administered 4 cycles of NAC followed by IDS and 4 cycles of 
postoperative chemotherapy within the study period. These patients were also included in the 
IDS group.
3. Statistical analysis
Categorical variables were compared using the χ2 test, while continuous variables were 
compared using the Mann-Whitney U test. For the survival analysis, PFS was defined as 
the period from the date of first chemotherapy to the date of first recurrence or death of 
any cause. OS was defined as the period from the date of first chemotherapy to the date of 
death of any cause. Survival curves were constructed using the Kaplan-Meier method, and 
a univariate log-rank test was used to assess statistical significance. Multivariate analyses 
for PFS and OS were performed using Cox proportional hazard model. In patients who 
underwent surgery, we calculated the sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), and accuracy of preoperative serum CA125 levels 
in predicting the possibility of achieving complete surgery after NAC. Receiver operating 
characteristic curve (ROC) analysis was demonstrated to seek the threshold of preoperative 
serum CA125 levels for predicting complete surgery after NAC. The cutoff point was selected 
based on the Youden index method [19]. For the analyses, the level of statistical significance 
was set at p<0.05. All statistical analyses were performed using SPSS version 19 for Mac (IBM 
Corp., Armonk, NY, USA).
RESULTS
1. Study population and clinicopathological characteristics
A total of 389 patients with ovarian, fallopian tube, and peritoneal cancer were identified 
during the study period. Of the 389 patients, 143 met the inclusion criteria and 246 were 
excluded because they underwent PDS, were classified as FIGO stage II, received <3 cycles 
of NAC, or had no surgical adaptation. Of these, 117 patients were in the IDS group and 26 
in the Add-C group (Fig. 1). Nine patients in the IDS group could not complete the adjuvant 
chemotherapy due to progressive disease (2 patients), patients' choices (2 patients), and 
occurrence of postoperative complications (4 patients). Of these 4 patients, 2 had intestinal 
perforation, 1 had cerebellar infarction, and 1 had depression. In the Add-C group, 6 patients 
did not undergo debulking surgery because of progressive or stable disease (4 patients) and 
patients' choices (2 patients). Two patients who refused surgery were expected to achieve 
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complete surgery. The median follow-up period was 38 months (range, 8–130 months). The 
patients' characteristics are summarized in Table 1. The median age was 61 years (range, 
36–87 years) in the IDS group and 62 years (range, 41–78 years) in the Add-C group, with no 
significant difference between the 2 groups. Compared with the Add-C group, the IDS group 
had higher serum CA125 levels before NAC and surgery (p<0.01; p=0.04); in the IDS and 
Add-C group, the median serum CA125 levels before NAC were 1,410 U/mL (range, 52–18,250 
U/mL) and 580 U/mL (range, 20–43,460 U/mL), and the median serum CA125 levels before 
surgery were 28 U/mL (range, 7–922 U/mL) and 17 U/mL (range, 5–195 U/mL). Compared 
with the Add-C group, the IDS group had higher proportion of patients classified as FIGO 
stage III (p=0.02). Several patients in the IDS and Add-C group had clinical T3 (95.7%, 
96.2%), had pathological serous carcinoma (96.6%, 96.2%), and achieved complete surgery 
(70.1%, 69.2%), with no significant differences. About half of the patients in the IDS and 
Add-C group had clinical N1 (45.3%, 50.0%), but without significant differences. Most of 
the patients (92.3%) in the IDS group were administered ≥6 cycles of chemotherapy, while all 
patients in the Add-C group were administered 6 cycles of chemotherapy. No patients were 
administered bevacizumab as the first-line chemotherapy in both groups.
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PDS    n=234
Stage IIB   n=1 
PD    n=2
No indication for operation n=6 
Refuse chemotherapy  n=1
Refuse surgery   n=2
Chemotherapy 3 cycles 　　n=143
Patients with pathologically confirmed ovarian, fallopian tube, and peritoneal cancer 
who received treatment at the National Cancer Center Hospital between August 2007 and December 2016　 n=389
PD    n=2
Refuse chemotherapy  n=3
Postoperative complications n=4
PD, SD        n=4
Refuse surgery       n=2
Chemotherapy 6 cycles　　n=26IDS　　n=117




Chemotherapy 6 cycles+debulking surgery n=20
Fig. 1. Number of patients included for analysis. One hundred seventeen patients were in the IDS group and 26 in the Add-C group. 
Add-C, additional chemotherapy; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PD, progressive disease; PDS, primary debulking surgery; 
SD, stable disease.
2. Prognostic factors for PFS and OS
During the follow-up period, 95 (81.2%) patients had recurrence and 60 (51.3%) died in the 
IDS group, while 23 (88.5%) patients had recurrence and 11 (42.3%) died in the Add-C group. 
Kaplan-Meier estimates of PFS and OS of the IDS and Add-C group are presented in Fig. 2. 
The median PFS and OS of the IDS group were 18 and 51 months, respectively. By contrast, 
the median PFS and OS of the Add-C group were 16 and 65 months, respectively. The 5-year 
PFS rate and 5-year OS rate of the IDS group were 14.2% (95% confidence interval [CI]=6.9%–
21.5%) and 43.0% (95% CI=32.4%–53.6%), respectively. On the contrary, the 5-year PFS rate 
and 5-year OS rate of the Add-C group were 9.2% (95% CI=0.0%–21.2%) and 47.8% (95% 
CI=23.8%–71.7%), respectively. There were no significant differences in PFS (p=0.23) and OS 
(p=0.70) between the IDS group and Add-C group.
Multivariate analysis on age, FIGO Stage, resection status after debulking surgery, number 
of chemotherapy cycles, and therapeutic plan revealed that resection status and number of 
chemotherapy cycles have significant effects on survival outcome, and an equivalent effects on 
PFS (hazard ratio [HR]=1.51; 95% CI=0.94–2.41) and OS (HR=1.03; 95% CI=0.53–2.01) in both 
groups. Patients with residual disease after surgery had worse PFS (HR=2.18; 95% CI=1.45–3.28) 
and OS (HR=2.33; 95% CI=1.43–3.79), whereas patients who received <6 cycles of chemotherapy 
had worse PFS (HR=5.30; 95% CI=2.56–10.99) and OS (HR=3.05; 95% CI=1.46–6.38) (Table 2).
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Table 1. Patients' characteristics (n=143)
Characteristics IDS (n=117) Add-C (n=26) p-value
Age (yr) 61 (36–87) 62 (41–78) 0.95
CA125 before NAC (U/mL) 1410 (52–18,250) 580 (20–4,346) <0.01
CA125 before surgery (U/mL) 28 (7–922) 17 (5–195) 0.04
FIGO stage (2014) 0.02
III 69 (59.0) 9 (34.6)
IV 48 (41.0) 17 (65.4)
TNM classification 0.92
cT1,2 5 (4.3) 1 (3.8)
cT3 112 (95.7) 25 (96.2)
cN0 64 (54.7) 13 (50.0) 0.66
cN1 53 (45.3) 13 (50.0)
Histological type 0.49
Serous 113 (96.6) 25 (96.2)
Endometrioid 1 (0.9) 0 (0.0)
Clear cell 3 (2.6) 1 (3.8)
Resection status 0.93
No residual 82 (70.1) 18 (69.2)
Residual 35 (29.9) 2 (7.7)
No operation 0 (0.0) 6 (23.1)
Number of chemotherapy cycles*
3 cycles 4 (3.4) 0 (0.0)
4 cycles 2 (1.7) 0 (0.0)
5 cycles 3 (2.6) 0 (0.0)
6 cycles 92 (78.6) 26 (100.0)
7 cycles 4 (3.4) 0 (0.0)
8 cycles 12 (10.3) 0 (0.0)
NAC
3 cycles 76 (65.0) 0 (0.0)
4 cycles 41 (35.0) 0 (0.0)
5 cycles 0 (0.0) 0 (0.0)
6 cycles 0 (0.0) 20 (76.9)
Values are presented as median (range) or number of patients (%).
Add-C, additional chemotherapy; CA125, cancer antigen 125; FIGO, International Federation of Gynecology and 
Obstetrics; IDS, Interval debulking surgery; NAC, neoadjuvant chemotherapy.
*NAC and postoperative chemotherapy.
3.  Threshold of preoperative serum CA125 levels for predicting complete 
surgery
ROC curve demonstrated the threshold of preoperative serum CA125 levels for predicting 
complete surgery after NAC (Fig. 3). The area under the curve (AUC) was 0.70. The cutoff 
level was 30 U/mL based on the Youden index method. The sensitivity, specificity, PPV, NPV, 
and accuracy were 66.0%, 64.9%, 83.5%, 41.4%, and 65.7%, respectively (Table 3).
DISCUSSION
Our study showed that the effect of administering 6 cycles of chemotherapy followed by 
debulking surgery on the survival of patients with advanced ovarian, fallopian tube, and 
peritoneum cancer was equivalent to that of IDS after 3 cycles of NAC followed by 3 cycles 
of postoperative chemotherapy. Additionally, achieving complete surgery, regardless of the 
timing of surgery, and the administration of ≥6 cycles of chemotherapy were considered as 
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Fig. 2. Kaplan-Meier estimates for PFS and OS of IDS and Add-C group. There were no significant differences in PFS (p=0.23) and OS (p=0.70) between the IDS 
group and Add-C group. 
Add-C, additional chemotherapy; IDS, interval debulking surgery; OS, overall survival; PFS, progression-free survival.
Table 2. The multivariate analysis of clinicopathological factors and survival outcomes
Factor PFS OS
HR (95% CI) p-value HR (95% CI) p-value
Age
<70 1 1
≥70 0.9 (0.57–1.40) 0.64 0.95 (0.53–1.71) 0.88
FIGO stage (2014)
III 1 1
IV 0.85 (0.58–1.26) 0.41 1.04 (0.64–1.70) 0.87
Resection status
No residual 1 1
Residual 2.18 (1.45–3.28) <0.01 2.33 (1.43–3.79) <0.01
Number of chemotherapy cycles*
≥6 1 1
<6 5.3 (2.56–10.99) <0.01 3.05 (1.46–6.38) <0.01
Therapeutic plan
IDS 1 1
Add-C 1.51 (0.94–2.41) 0.09 1.03 (0.53–2.01) 0.94
Add-C, additional chemotherapy; CI, confidence interval; FIGO, International Federation of Gynecology and 
Obstetrics; HR, hazard ratio; IDS, interval debulking surgery; OS, overall survival; PFS, progression-free survival.
*Neoadjuvant chemotherapy and postoperative chemotherapy.
favorable prognostic factors. Furthermore, our findings suggest that a preoperative serum 
CA125 level of ≤30 U/mL is a useful predictor of achieving complete surgery in patients with 
ovarian cancer treated with NAC.
Univariate and multivariate analyses revealed that administering 6 cycles of NAC followed 
by debulking surgery had equivalent effects on the PFS and OS compared with the IDS 
group. However, the association between NAC and postoperative chemotherapy cycles and 
prognosis of patients with advanced ovarian cancer remained unclear. Additionally, previous 
studies evaluating the relationship between NAC cycles and prognosis had conflicting 
results. Compared with ≤4 cycles of NAC, previous studies reported that ≥5 cycles of NAC 
had equivalent effects on PFS and OS [7,10,11], while others reported poor prognosis [9,12]. 
With regard to postoperative chemotherapy, Chung et al. [8] reported that >3 cycles of 
postoperative chemotherapy had no benefit in a group of patients who achieved complete 
radiological remission after 3 cycles of postoperative chemotherapy. Our treatment strategy 
is unique compared with these previous studies. In our institutions, patients administered 
with 6 cycles of NAC did not usually receive postoperative chemotherapy. The patients' 
characteristics including those reported in these studies were different from those of other 
previous studies. Compared with the Add-C group, the IDS group had higher serum CA125 levels 
before NAC. We believed that this difference did not influence the treatment decision because 
we did not refer to serum CA125 levels before NAC for surgical indication of IDS. However, 
there was a significant difference in serum CA125 levels before NAC between the IDS group 
and the Add-C group. As a result, selection bias might have influenced the survival outcomes.
Multivariate analyses revealed that complete surgery and administering ≥6 cycles of 
chemotherapy were independent favorable prognostic factors. Phillips et al. [10] reported 
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Fig. 3. ROC demonstrating the predictive ability of preoperative serum CA125 levels. 
CA125, cancer antigen 125; ROC, receiver operating characteristic curve.
Table 3. Associations of preoperative serum CA125 levels with resection status after surgery
Preoperative CA125 levels No residual Residual Total
≤30 U/mL 66 13 79
<30 U/mL 34 24 58
Total 100 37 137
Sensitivity, 66.0%; specificity, 64.9%; positive predictive value, 83.5%; negative predictive value, 41.4%; accuracy, 65.7%.
CA125, cancer antigen 125.
that complete surgery remains a significant independent marker of survival in patients 
undergoing surgery even after 5 cycles of NAC. This result is similar to those reported 
in our study. Since complete surgery is important for patients' prognosis, performing 
debulking surgery in a period when complete surgery is expected may be better than 
performing on schedule regardless of chemotherapy responses. Chung et al. [8] reported 
that at least 6 cycles of total chemotherapy (NAC and postoperative adjuvant chemotherapy) 
is an independent prognostic factor in patients treated with NAC, IDS, and postoperative 
chemotherapy. This result was also similar with our findings. Administering 6 cycles of 
chemotherapy followed by debulking surgery had significant advantages. Several types 
of radical surgeries, such as bowel resection, diaphragm stripping, splenectomy, and so 
on, were also performed to achieve complete surgery, and only a few complications were 
reported. Some patients did not receive postoperative chemotherapy after undergoing IDS. In 
this study, postoperative chemotherapy was not administered in four patients who developed 
postoperative complications. In particular, 2 patients had intestinal perforation caused by 
IDS. Hence, 6 cycles of chemotherapy followed by debulking surgery may be suitable for 
patients who require radical surgery to achieve complete surgical resection.
About 37 out of 137 (27.0%) patients who underwent debulking surgery had residual disease; 
nevertheless, patients who were expected to achieve complete surgery based on the following 
factors were scheduled for surgery: patients' performance status, pelvic exam, and image 
findings such as computed tomography, magnetic resonance imaging, and echo. Some 
patients had multiple microscopic peritoneum metastases at the mesentery, which were not 
detected during preoperative imaging. Hence, it was difficult to completely remove such 
visceral multiple peritoneum metastases. Our study suggested that a preoperative serum 
CA125 level of ≤30 U/mL was a useful predictor of achieving complete surgery. The PPV 
was high (83.5%); therefore, complete surgery could be achieved if the preoperative serum 
CA125 level was ≤30 U/mL. Some previous studies reported CA125 cutoff value as a predictor 
of achieving complete surgery after NAC in patients with advanced ovarian cancer [13-17]. 
Furukawa et al. reported that the preoperative serum CA125 level of ≤20 U/mL was considered 
as the cutoff value that predicts complete surgical resection in patients who underwent IDS 
[13]. All patients in this study underwent IDS after 3 cycles of NAC. Pelissier et al. [14] reported 
that the preoperative serum CA125 level of ≤75 U/mL after 3 cycles of NAC was a predictor of 
achieving complete surgical resection in patients who underwent IDS. The specificity and the 
NPV were 73.6% and 68.4%, respectively [14]. All study patients underwent IDS after each 
cycle of NAC, and the median NAC cycle was 6. Rodriguez et al. [16] reported that patients 
with a preoperative CA125 level of ≤100 U/mL had a higher likelihood of achieving complete 
surgical resection compared with those who had a preoperative CA125 level of >100 U/mL 
(HR=2.6; 95% CI=1.05–6.5). Serum CA125 was measured preoperatively, and the number 
of NAC cycles varied in this study. The differences in optimal thresholds for CA125 may be 
due to the differences in patients' characteristics, such as CA125 measurement timing, NAC 
cycles, and the rate of complete surgery. Our date may not be sufficient to predict complete 
surgical resection because of low NPV (41.4%) and accuracy (65.7%). Therefore, further 
studies are necessary to determine other effective predictors.
The present study had several limitations. The judgement of resectability depended on 
physician's decision, even though it was discussed at the conference attended by some 
gynecologic oncologists. Thus, it may be difficult to generalize the findings of the present 
study. The number of patients in the Add-C group was limited. Hence, more large-scale 
cohort studies should be performed in the future to validate the findings of our study.
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In conclusion, with regard to the treatment of advanced ovarian, fallopian tube, and peritoneum 
cancer, complete surgery and ≥6 cycles of chemotherapy are independent favorable prognostic 
factors, and preoperative serum CA125 level of ≤30 U/mL may be a useful predictor of complete 
surgery in patients treated with NAC. After 3 cycles of NAC, administering additional 3 cycles 
of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as 
IDS followed by 3 cycles of postoperative chemotherapy, although the number of included 
patients in the Add-C group was small. Therefore, administering additional 3 cycles of 
chemotherapy followed by debulking surgery might be preferable for patients who are not 
expected to achieve complete surgery after 3 cycles of NAC. However, further larger-scale 
studies are necessary to validate the findings of the present study.
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